Advertisement

Tumor Biology

, Volume 35, Issue 8, pp 8209–8216 | Cite as

Aberrant promoter methylation of HIN-1 gene may contribute to the pathogenesis of breast cancer: a meta-analysis

  • Di Dai
  • Xi-Hua Dong
  • Shi-Tong Cheng
  • Ge Zhu
  • Xiao-Lin Guo
Research Article

Abstract

We conducted the present meta-analysis of relevant cohort studies to evaluate whether promoter methylation of the high in normal-1 (HIN-1) gene contributes to breast cancer. The MEDLINE (1966 ~ 2013), Cochrane Library (Issue 12, 2013), EMBASE (1980 ~ 2013), CINAHL (1982 ~ 2013), Web of Science (1945 ~ 2013), and Chinese Biomedical (CBM) (1982 ~ 2013) databases were searched without any language restrictions. Meta-analyses were conducted using Stata software (version 12.0; Stata Corporation, College Station, TX, USA). Crude odds ratios (ORs) with their 95 % confidence interval (CI) were calculated. Nine clinical cohort studies that enrolled a total of 693 breast cancer patients were included in the meta-analysis. The results of our meta-analysis demonstrated that HIN-1 methylation frequency in cancer tissue was significantly higher than that of normal and benign tissues (cancer tissue vs. normal tissue: OR = 52.60, 95 % CI = 33.77 ~ 81.92, P < 0.001; cancer tissue vs. benign tissue: OR = 2.38, 95 % CI = 1.53 ~ 3.70, P < 0.001; respectively). Ethnicity-stratified analysis indicated that HIN-1 promoter methylation was correlated with the pathogenesis of breast cancer among both Asians and Caucasians (all P < 0.05). Our findings provide empirical evidence that aberrant HIN-1 promoter methylation may contribute to the pathogenesis of breast cancer. Thus, aberrant HIN-1 promoter methylation could be an independent and important biomarker used in predicting the prognosis and progression of breast cancer.

Keywords

HIN-1 Promoter methylation Breast cancer Meta-analysis 

Notes

Acknowledgments

The study was funded by Specification of Individual Medical Testing, Standardization Research and Application (The 2014 annual public industry research) (201402018). We would like to acknowledge the helpful comments on this paper received from our reviewers.

Conflicts of interest

None.

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.PubMedCrossRefGoogle Scholar
  3. 3.
    Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378(9801):1461–84.PubMedCrossRefGoogle Scholar
  4. 4.
    Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O’Meara ES, et al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med. 2012;156(9):635–48.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Campa D, Kaaks R, Le Marchand L, Haiman CA, Travis RC, Berg CD, et al. Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium. J Natl Cancer Inst. 2011;103(16):1252–63.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Barnett GC, Shah M, Redman K, Easton DF, Ponder BA, Pharoah PD. Risk factors for the incidence of breast cancer: do they affect survival from the disease? J Clin Oncol. 2008;26(20):3310–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Park SK, Kim Y, Kang D, Jung EJ, Yoo KY. Risk factors and control strategies for the rapidly rising rate of breast cancer in Korea. J Breast Cancer. 2011;14(2):79–87.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Hill VK, Ricketts C, Bieche I, Vacher S, Gentle D, Lewis C, et al. Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. Cancer Res. 2011;71(8):2988–99.PubMedCrossRefGoogle Scholar
  9. 9.
    Sun Z, Asmann YW, Kalari KR, Bot B, Eckel-Passow JE, Baker TR, et al. Integrated analysis of gene expression, CpG island methylation, and gene copy number in breast cancer cells by deep sequencing. PLoS ONE. 2011;6(2):e17490.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Tomita T, Kimura S. Regulation of mouse Scgb3a1 gene expression by NF-Y and association of CpG methylation with its tissue-specific expression. BMC Mol Biol. 2008;9:5.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, et al. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res. 2007;9(4):R57.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Ahlquist T, Lind GE, Costa VL, Meling GI, Vatn M, Hoff GS, et al. Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. Mol Cancer. 2008;7:94.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Wu Q, Lothe RA, Ahlquist T, Silins I, Trope CG, Micci F, et al. DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets. Mol Cancer. 2007;6:45.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Krop IE, Sgroi D, Porter DA, Lunetta KL, LeVangie R, Seth P, et al. HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. Proc Natl Acad Sci U S A. 2001;98(17):9796–801.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Guo M, Ren J, Brock MV, Herman JG, Carraway HE. Promoter methylation of HIN-1 in the progression to esophageal squamous cancer. Epigenetics. 2008;3(6):336–41.PubMedCrossRefGoogle Scholar
  16. 16.
    Gong Y, Guo MZ, Ye ZJ, Zhang XL, Zhao YL, Yang YS. Silence of HIN-1 expression through methylation of its gene promoter in gastric cancer. World J Gastroenterol. 2011;17(4):526–33.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Lee JS, Fackler MJ, Teo WW, Lee JH, Choi C, Park MH, et al. Quantitative promoter hypermethylation profiles of ductal carcinoma in situ in North American and Korean women: potential applications for diagnosis. Cancer Biol Ther. 2008;7(9):1398–406.PubMedCrossRefGoogle Scholar
  18. 18.
    Verschuur-Maes AH, de Bruin PC, van Diest PJ. Epigenetic progression of columnar cell lesions of the breast to invasive breast cancer. Breast Cancer Res Treat. 2012;136(3):705–15.PubMedCrossRefGoogle Scholar
  19. 19.
    Twelves D, Nerurkar A, Osin P, Dexter T, Ward A, Gui GP, et al. DNA promoter hypermethylation profiles in breast duct fluid. Breast Cancer Res Treat. 2013;139(2):341–50.PubMedCrossRefGoogle Scholar
  20. 20.
    Park SY, Kwon HJ, Lee HE, Ryu HS, Kim SW, Kim JH, et al. Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch. 2011;458(1):73–84.PubMedCrossRefGoogle Scholar
  21. 21.
    Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Zintzaras E, Ioannidis JP. HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics. 2005;21(18):3672–3.PubMedCrossRefGoogle Scholar
  23. 23.
    Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295(6):676–80.PubMedCrossRefGoogle Scholar
  24. 24.
    Fackler MJ, McVeigh M, Evron E, Garrett E, Mehrotra J, Polyak K, et al. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer. 2003;107(6):970–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Feng W, Orlandi R, Zhao N, Carcangiu ML, Tagliabue E, Xu J, et al. Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers. BMC Cancer. 2010;10:378.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Kim JH, Shin MH, Kweon SS, Park MH, Yoon JH, Lee JS, et al. Evaluation of promoter hypermethylation detection in serum as a diagnostic tool for breast carcinoma in Korean women. Gynecol Oncol. 2010;118(2):176–81.PubMedCrossRefGoogle Scholar
  27. 27.
    Shigematsu H, Suzuki M, Takahashi T, Miyajima K, Toyooka S, Shivapurkar N, et al. Aberrant methylation of HIN-1 (high in normal-1) is a frequent event in many human malignancies. Int J Cancer. 2005;113(4):600–4.PubMedCrossRefGoogle Scholar
  28. 28.
    Buchmann RC, Asad S, Wolf JN, Mohannath G, Bisaro DM. Geminivirus AL2 and L2 proteins suppress transcriptional gene silencing and cause genome-wide reductions in cytosine methylation. J Virol. 2009;83(10):5005–13.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Di Dai
    • 1
  • Xi-Hua Dong
    • 1
  • Shi-Tong Cheng
    • 1
  • Ge Zhu
    • 1
  • Xiao-Lin Guo
    • 1
  1. 1.Department of Laboratory MedicineThe First Hospital of China Medical UniversityShenyangPeople’s Republic of China

Personalised recommendations